Replies to post #806267 on NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

So when I don’t agree with one of the disciples it’s misdirection? Got it. I told you my belief. Again, all one of you groupies have to do is ask the company and copy paste their response here, or even better have them put it up on their website or in a filing. Because the only UCLA contract I’ve ever seen is ancient and vague. But no, instead the question is never asked and we all argue year after year over it. But I think that’s how the disciples prefer it?

[learningcurve2020]

Here, this is from another biotech’s 10q and it took me one minute to find for you. Now go review NWBO’s 10q and compare the level of detail. Please let us all know what you find.

>>License Agreement with the Baylor College of Medicine
In March 2018, the Company entered into an exclusive license agreement with BCM under which the Company acquired a worldwide, exclusive license to BCM's rights in and to certain intellectual property rights, including a European patent to develop and commercialize MAR-T cell product candidates (the "BCM License Agreement"). In exchange for the license, the Company issued shares of its common stock to BCM valued at approximately $5.0 million at the time of issuance, agreed to make royalty payments to BCM upon commercial sales according to the royalty schedule in the BCM License Agreement, under which the royalty percentages increase in proportion to the aggregate net sales, and agreed to pay BCM certain milestone payments up to an aggregate of $64.85 million. The milestone payments are based upon the occurrence of nine particular milestones relating to completion of the first dosing in clinical trials for a first and second distinct product, FDA approval, and achievement of certain net sales goals. The Company is also responsible for sublicensing fees and for reimbursing BCM for related-party expenses. In addition, upon a liquidity event (as defined in the BCM License Agreement) of the Company, BCM will receive a one-time liquidity incentive payment of 0.5% of the liquidity event proceeds (as defined in the BCM License Agreement).